28 research outputs found
Transcriptional correlates of the pathological phenotype in a Huntington’s disease mouse model
Huntington disease (HD) is a fatal neurodegenerative disorder without a cure that is caused by an
aberrant expansion of CAG repeats in exon 1 of the huntingtin (HTT) gene. Although a negative
correlation between the number of CAG repeats and the age of disease onset is established, additional
factors may contribute to the high heterogeneity of the complex manifestation of symptoms
among patients. This variability is also observed in mouse models, even under controlled genetic
and environmental conditions. To better understand this phenomenon, we analysed the R6/1 strain
in search of potential correlates between pathological motor/cognitive phenotypical traits and
transcriptional alterations. HD-related genes (e.g., Penk, Plk5, Itpka), despite being downregulated
across the examined brain areas (the prefrontal cortex, striatum, hippocampus and cerebellum),
exhibited tissue-specific correlations with particular phenotypical traits that were attributable to
the contribution of the brain region to that trait (e.g., striatum and rotarod performance, cerebellum
and feet clasping). Focusing on the striatum, we determined that the transcriptional dysregulation
associated with HD was partially exacerbated in mice that showed poor overall phenotypical scores,
especially in genes with relevant roles in striatal functioning (e.g., Pde10a, Drd1, Drd2, Ppp1r1b).
However, we also observed transcripts associated with relatively better outcomes, such as Nfya
(CCAAT-binding transcription factor NF-Y subunit A) plus others related to neuronal development,
apoptosis and differentiation. In this study, we demonstrated that altered brain transcription can be
related to the manifestation of HD-like symptoms in mouse models and that this can be extrapolated to
the highly heterogeneous population of HD patients
Microglia activation in a model of retinal degeneration and TUDCA neuroprotective effects
Background: Retinitis pigmentosa is a heterogeneous group of inherited neurodegenerative retinal disorders characterized by a progressive peripheral vision loss and night vision difficulties, subsequently leading to central vision impairment. Chronic microglia activation is associated with various neurodegenerative diseases including retinitis pigmentosa. The objective of this study was to quantify microglia activation in the retina of P23H rats, an animal model of retinitis pigmentosa, and to evaluate the therapeutic effects of TUDCA (tauroursodeoxycholic acid), which has been described as a neuroprotective compound. Methods: For this study, homozygous P23H line 3 and Sprague-Dawley (SD) rats were injected weekly with TUDCA (500 mg/kg, ip) or vehicle (saline) from 20 days to 4 months old. Vertical retinal sections and whole-mount retinas were immunostained for specific markers of microglial cells (anti-CD11b, anti-Iba1 and anti-MHC-II). Microglial cell morphology was analyzed and the number of retinal microglial was quantified. Results: Microglial cells in the SD rat retinas were arranged in regular mosaics homogenously distributed within the plexiform and ganglion cell layers. In the P23H rat retina, microglial cells increased in number in all layers compared with control SD rat retinas, preserving the regular mosaic distribution. In addition, a large number of amoeboid CD11b-positive cells were observed in the P23H rat retina, even in the subretinal space. Retinas of TUDCA-treated P23H animals exhibited lower microglial cell number in all layers and absence of microglial cells in the subretinal space. Conclusions: These results report novel TUDCA anti-inflammatory actions, with potential therapeutic implications for neurodegenerative diseases, including retinitis pigmentosa.This research was supported by grants from the Spanish Ministry of Economy and Competitiveness-FEDER (BFU2012-36845), Instituto de Salud Carlos III (RETICS RD12/0034/0010), Organización Nacional de Ciegos Españoles (ONCE), FUNDALUCE, Asociación Retina Asturias and Fundación Jesús de Gangoiti